Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read More
    Services
    Adaptive TrialsClinical Research ServicesConsultingEarly PhaseFunctional Services ProvisionLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions Value Access Outcomes
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read More
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Serving governments, multinational public health organisations, and global NGOs.
    Government and Public Health Solutions

    Serving governments, multinational public health organisations, and global NGOs.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read More
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersGenomicsInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
    Oncology

    ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.

    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.
    Vaccines

    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read More
    Innovation
    FIRECRESTSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGE Medical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMS
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Connecting patients with the right trial in the right location.
    Patient Engagement Platform

    Connecting patients with the right trial in the right location.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read More
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Aggregated news on COVID-19 clinical trials.
    Coronavirus Observatory

    Aggregated news on COVID-19 clinical trials.

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read More
    News & Events
    Press ReleasesIn the NewsEventsMediakitSocial MediaAwards
    Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects.
    ICON supports Pfizer and BioNTech on COVID-19 vaccine trial

    Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects.

    3 February, 2021
    Webinar: FT Digital Dialogues: Building resilience in pharma R&D by decentralising and digitising

    3 February, 2021

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read More
    About ICON
    Company HistoryICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON is committed to making a positive impact on our people, environment and our community.
    Environmental, Social & Governance

    ICON is committed to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • EN | 日本語
  1. Home
  2. News & Events
  3. Press Releases

Press Releases

  • 24 July 2019

    ICON Reports Second Quarter 2019 Results

    Net business wins (including pass-through) in the quarter of $901 million; a book to bill of 1.30.

  • 24 July 2019

    ICON announces the appointment of Ms. Julie O’Neill to Board of Directors

    And confirms the retirement of Professor Dermot Kelleher and Mr. Declan McKeon

  • 2 July 2019

    Forbes names ICON in list of Best Employers in America for Women

    ICON recognised as top employer for women in anonymous survey of 60,000 employees.

  • 24 June 2019

    ICON and DIA driving Insights to Action with DIA Live 2019

    DIA Live combines powerful AI analysis and data visualisation features of news and social media conversations at DIA Global Annual Meeting.

  • 23 May 2019

    ICON’s Acquisition of MeDiNova Research

    The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.

  • 13 May 2019

    ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research

    ICON Wins Multiple Awards at the 2019 Clinical and Research Excellence Awards

  • 9 May 2019

    ICON Launches New Patient Engagement Platform to Support Improved Patient Experience & Enrolment in Clinical Trials

    Increasing visibility of potential study participants to sites and sponsors.

  • 1 May 2019

    ICON Reports First Quarter 2019 Results

    Net business wins (including pass-through) in the quarter of $885 million; a book to bill of 1.31.

  • 25 April 2019

    Forbes names ICON one of the best employers in America

    ICON ranked top CRO in anonymous survey of 50,000 employees across 38 sectors

  • 5 March 2019

    ICON wins multiple categories in 2019 CRO Leadership Awards

    ICON recognised for specialised services offering across product development lifecycle

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • ...
  • 11
In this section
In this section
  • Press Releases
  • In the News
  • Events
    • Industry Events
    • Webinars
    • Workshops
  • Mediakit
    • Facts and figures
    • ICON Spokespeople
  • Social Media
  • Awards
  • ICON supports Pfizer and BioNTech on COVID-19 vaccine trial
  • Webinar: FT Digital Dialogues: Building resilience in pharma R&D by decentralising and digitising

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content Preferences
ICON For
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press Releases
  • Mediakit
  • Events
  • Social Media Dashboard
  • Coronavirus Observatory
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2021 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies

Connect with us

Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media